Meta-Analysis Probes Cancer Risk Concern for JAK Inhibitors Meta-Analysis Probes Cancer Risk Concern for JAK Inhibitors

Although no increased cancer risk was seen vs methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than were tumor necrosis factor inhibitors in a meta-analysis.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news